Idiopathic pulmonary fibrosis

Respiratory system
#Cambrian BioPharma #Idiopathic pulmonary fibrosis #Isterian Biotech #Mergers and acquisitions

Cambrian expands fibrosis pipeline

Cambrian BioPharma has unveiled its latest pipeline company, Isterian Biotech.   The preclinical start-up is working towards the development of first-in-class small molecule inhibitors of transglutaminase 2 (TG2), one of the major crosslinking enzymes in the human body, which becomes more active during ageing, resulting in fibrotic diseases.  With age a… Read More

#Business & Investment #News

#Antibiotic resistance #Antibiotics #Contraception #Contraceptive pill #Covid-19 #Drug development #Drug discovery #Idiopathic pulmonary fibrosis #Respiratory syncytial virus

This week in drug discovery (17-21 October)

News round-up for 17-21 October by DDW Digital Content Editor Diana Spencer  Amid continued concern about antibiotic resistance, the headline news this week was the discovery of a new antibiotic that could be effective against some of the most treatment-resistant pathogens.   However, there was also… Read More

#News

Woman doing clinical research
#Computational chemistry #Drug discovery #Drug repurposing #Idiopathic pulmonary fibrosis #Lung disease #Medicines repurposing #Preclinical investigations

Cancer drug shows promise in treating incurable lung disease 

Researchers have shown that the medication saracatinib shows promise as a treatment for idiopathic pulmonary fibrosis (IPF).   Saracatinib worked as well or better than two approved drugs at reducing tissue scarring in preclinical models of IPF according to the study published in the American Journal of… Read More

#News

Chest CT images
#AI #Artificial intelligence (AI) #Idiopathic pulmonary fibrosis #Imaging #Lung disease

Phase II IPF trial to benefit from AI imaging

Brainomix has partnered with Bridge Biotherapeutics to deliver AI imaging biomarker analysis within the Phase II study of novel autotaxin inhibitor BBT-877 in idiopathic pulmonary fibrosis (IPF). Under the partnership, Brainomix will leverage its e-ILD technology (automated artificial intelligence software) which has been trained to process high resolution chest CT… Read More

#News

#Boehringer Ingelheim #Clinical trial #Idiopathic pulmonary fibrosis

Boehringer Ingelheim reports positive data for lung therapy  

Boehringer Ingelheim’s investigational therapy for idiopathic pulmonary fibrosis (IPF) has shown positive data in a Phase II clinical trial, the company has announced.   The company is investigating its oral phosphodiesterase 4B (PDE4B) inhibitor (BI 1015550) as a potential treatment for people with IPF.   In a… Read More

#News